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Abstract  (204 words) 
 
Purpose: To evaluate the reliability and renal safety of an original schedule of high-dose 
methotrexate (HDMTX) administration with hyper-alkalinization, and without hyper-
hydration. 
Methods: Osteosarcoma patients received HDMTX (8-12 g/m²) as a 4-hour infusion. 
Hypertonic 8.4% sodium bicarbonate was infused prior to HDMTX, then once daily for 3 
days. Methotrexate serum concentrations was measured at hour 4 (Cmax), hour 24, hour 48 
and hour 72. Urinary pH was measured on each miction. Serum creatinine was assessed on 
days 1, 3 and 8. 
Results: Twenty-six patients (median age: 18 years, range: 15-25) received a total of 344 
cycles of HDMTX, including 16 patients treated in an outpatient basis. Urinary pH remained 
constantly higher than 7.5 in all patients. Grade 1 creatininemia toxicity was observed in 31 
cycles (9%), and grade 2 creatinine toxicity was observed in one patient. No episode of acute 
severe nephrotoxicity was observed. No significant worsening was observed in serum 
creatinine and calculated creatinine clearance from baseline to the end of therapy (p = 0.74). 
The main extra-renal toxicity was alkalinization-related hypokalemia from H48. No re-
hospitalisation was required. 
Conclusion: Hyper-alkalinization appears an efficient and reliable method to prevent the 
acute renal toxicity of HDMTX, and allows its safe administration in the outpatient setting. 
 





Osteosarcoma (OS) is a rare malignant tumour that mainly afflicts children and young adults. 
Prior to the introduction of systemic chemotherapy, approximately 80%-90% of patients died 
despite early radical surgery [1]. Neoadjuvant chemotherapy dramatically improved the 
disease-free survival and overall survival for OS patients, and is considered the gold standard 
treatment modality [2,3]. 
  
The most effective drugs in OS are: cisplatin, doxorubicin, ifosfamide and high-dose 
methotrexate (HDMTX) [4,5]. These drugs are always administered sequentially, because 
HDMTX-induced nephrotoxicity makes its administration with cisplatin or ifosfamide at high 
risk. The standard administration of HDMTX includes hyper-hydration, typically: 2.5-3.5 
l/m²/24h (beginning 12h before HDMTX infusion, for 36-48h). Close monitoring of urinary 
pH is mandatory, with administration sodium bicarbonate before and after the infusion (45-50 
mEq per liter of IV fluids), in order to maintain alkaline urinary pH [6]. However, this 
standard protocol shows several limitations. Firstly, hyper-hydration may obscure the ability 
to reach the threshold peak [7,8] and AUC (area under the concentration vs. time curve) [9] 
required to ensure the efficacy of HDMTX in OS. Hence, hyper-hydration rapidly decreases 
the plasma-to-tissue concentration gradient of methotrexate (MTX) and might reduce its anti-
tumoral effect [10,11]. Secondly, the a posteriori administration of oral or IV sodium 
bicarbonate does not reverse the renal damage caused by HDMTX in all cases, and a sizeable 
proportion of patients develop progressive renal function impairment after HDMTX-based 
chemotherapy [12]. Thirdly, Sand et al. [13] showed that maintaining an alkaline urinary pH 
was more important than maintaining high urinary flow to obtain optimal HDMTX clearance. 
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Finally, a close fortnightly monitoring of urinary pH requires careful nursing care, as well as 
the cooperation of patients that may be difficult to obtain.  
 
In view of these limitations, a strong and preventive - instead of a posteriori – urine 
alkalinization would be a coherent approach in view of the pathogenesis of HDMTX induced 
acute nephrotoxicity. Indeed, HDMTX-induced nephrotoxicity is mainly mediated by the 
precipitation of MTX and its metabolites in the renal tubules [14]. The solubility of MTX and 
its metabolites is closely related to urinary pH (Table 1) [15].  
 
As a consequence, we hypothesized that: i) an aggressive strategy of preventive urine 
alkalinization could prevent HDMTX-induced acute nephrotoxicity; ii) renal safety provided 
by hyper-alkalinization could allow withdrawing the commonly used hyper-hydration 
following HDMTX infusion, and therefore provide optimal peak and AUC; iii) this 
simplified, patient-friendly method of administration could facilitate nursing care and allow 
the outpatient administration of HDMTX. 
The present study aimed to demonstrate the reliability and renal safety of a new schedule of 
HDMTX administration with hyper-alkalinization, and without hyper-hydration. 
 
 
Patients and methods 
 
From 2001 to 2007, 26 patients with newly diagnosed, high grade OS were treated in our 
institution using a specific hyper-alkalinization protocol for HDMTX administration, as 
described below. The first ten patients were treated in the inpatient setting. Given the good 
tolerability of this regimen, the 16 following patients were treated in the outpatient setting. 
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The study was approved by the local ethics committee, and informed consent was obtained 
from each patient or guardian. The medical records of each patient were prospectively entered 
in a computed database. Patients had received no previous anticancer therapy, and had a 
normal baseline renal function. They had no concomitant disease potentially leading to acute 
renal dysfunction.  
 
Treatment protocol 
Patients received pre-operative chemotherapy for 8 weeks, followed by 2 weeks off treatment 
before radical excision surgery was performed. HDMTX was given as a single agent (8-12 
g/m²) on day 1, then on days 8 and 15. In addition, patients received ifosfamide (5 g/m², 4 
courses), cisplatin (100 mg/m², 1 course) and doxorubicin (60 mg/m², 2 courses) given 
sequentially, as previously described [16-18]. Anti-emetic prophylaxis included anti-5HT3 
and corticosteroids at standard doses. From 2006, anti-NK1 (aprepitant) was added to this 
regimen. Within 6 weeks after surgery, patients received adjuvant chemotherapy based on the 
same regimen in good responders to pre-operative chemotherapy.  
 
Administration of HDMTX 
Patients received 500 ml of 8.4% sodium bicarbonate (500 mEq, B Braun Medical, Boulogne-
Billancourt, France) over 1 h before HDMTX infusion (day 1), then on days 2, 3 and 4. From 
day 1 to day 4, patients also received 4 g (53.6 mEq) of KCl daily IV supplementation. The 
dose of HDMTX was 8 g/m² (4 patients) or 12 g/m² (22 patients). HDMTX dose was diluted 
in 500 ml of 0.9% NaCl and infused over a 4 h period. HDMTX was not followed by forced 
hydration, and the IV route was stopped for the following 20 hours. Leucovorin rescue was 
introduced 24 hr after start of HDMTX infusion (20 hr after completion of the 4 hour 
infusion) [6]. Dose of folinic acid was subsequently adjusted as a function of serum 
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methotrexate levels, as previously described (Table 2) [12,15]. On day 4, leucovorin was 
discontinued and patients were discharged to home once serum methotrexate levels reached 
≤0.1 mM/L. Patients received the instruction to maintain oral hydration >2L per 24 h for 3 
consecutive days upon discharge. 
 
Sample and pharmacokinetics analysis 
Urinary pH was measured on each miction for 3 days following HDMTX infusion. Serum 
creatinine was measured on days 1, 3 and 8.  Methotrexatemia was measured at H0, H4 
(Cmax), H24, H48 and H72. HDMTX pharmacokinetic parameters were estimated using the 
software package Thermo Kinetica 4.4 (Inna Phase Corp., USA) and assuming a non-
compartmental analysis (NCA).  
 
Analysis of toxicity 
Creatinine clearance was calculated according to the Cockroft and Gault formula [24]. The 
degree of nephrotoxicity and other adverse events were graded according to the National 
Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 2.0. In 
addition to short-term toxicities, we investigated whether this method of administration of 
HDMTX induced progressive renal dysfunction, defined as a significant increase of serum 
creatinine or decrease in calculated creatinine clearance, from baseline to the end of treatment.  
 
Statistical analysis 
Student’s t test was used to analyse changes of serum creatinine and calculated creatinine 
clearance from baseline to the end of treatment. Calculations were performed with NCSS 






Patients characteristics are summarized in Table 3. Amongst the 26 patients (9 females, 17 
males), the primary tumour site was axial in 4 patients (15%), and limbs in 22 patients (85%). 
Three patients (11.5%) had synchronous lung metastases. The median age was 18 years 
(range: 15-25). A total of 344 cycles, including the pre-operative and post-operative 
treatments, were evaluable for toxicity and for HDMTX pharmacokinetics (Table 4). 
 
Renal safety of HDMTX given with hyper-alkalinisation and without hyper-hydration 
Urinary pH remained constantly higher than 7.5 in all patients. In 31 cycles (9%) of HDMTX, 
reversible creatininemia elevation (grade 1, < 1.5 ULN) was noticed. Grade 2 creatinine 
elevation was observed in one patient. No episode of acute severe nephrotoxicity was 
observed. Regarding progressive renal dysfunction, no significant worsening was observed in 
serum creatinine and calculated creatinine clearance from baseline to the end of therapy (p = 
0.74) (Table 1). No patient required the administration of carboxypeptidase. 
 
Extra-renal toxicity 
Toxicity included manageable grade 1-2 nausea and emesis in all patients, and grade 2 
transaminase elevation in 42% of patients. Grade 3 neutropenia occurred in 65 % of patients, 
and febrile neutropenia in 1 patient. Grade 1-2 mucositis occurred in 26% of patients. 
The main acute toxicity was grade 3 hypokaliemia, which occurred in 5 patients. Because 
hypokaliemia was not associated with serum creatinine elevation, it was supposed to be 
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secondary to hyper-alkalinization. Hence, hypokaliemia was easily managed with IV or oral 
KCl supplementation from H24. No grade 4 toxicity occurred.  
 
Although the activity of this regimen was not the endpoint of the study, we observed 
pathological tumor necrosis rates following pre-operative chemotherapy within the expected 




In the previously described chemotherapy protocols in OS patients, HDMTX was always 
administered sequentially with other active drugs (cisplatin and ifosfamide) because of its 
threatening nephrotoxicity. Such neoadjuvant protocols were scheduled over more than 10 
weeks, thus lowering chemotherapy dose-intensity, in spite of the theoretical knowledge that 
dose-intensive treatments warrant a better efficacy in chemosensitive tumours [8,20]. Hence, 
the optimal neoadjuvant chemotherapy regimen in OS remains to define, and better ways to 
increase dose intensity with acceptable toxicity could possibly improve results. 
 
The aim of this study was to optimize HDMTX administration by avoiding its nephrotoxicity 
with aggressive hyper-alkalinization, and to assess the impact of the lack of forced hydration 
on the pharmacokinetics of HDMTX. There was an obvious intra-patient and inter-patient 
variability in HDMTX serum concentrations, as previously described in the literature [21,22]. 
We demonstrated that the administration of HDMTX with hyper-alkalinization and without 
forced hydration is a safe and reliable method to prevent nephrotoxicity: over 344 cycles, no 
acute renal dysfunction was noticed. Urinary pH remained stable and > 7.5, avoiding 
precipitation of MTX and its metabolites in the renal tubules. In previous studies, the overall 
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incidence of significant acute nephrotoxicity was close to 1.8% [14], whereas another case 
series reported 30% of patients had a doubling of the baseline serum creatinine [12]. Acute 
nephrotoxicity was seen in 4% of patients in the present case series of 344 cycles, a 
proportion that favourably compares with previously published data. 
 
Besides, the lack of forced hydration did not significantly altered HDMTX pharmacokinetics. 
The threshold peak (700-1000 µmol/l) [9] recommended to ensure the efficacy of HDMTX in 
OS were easily reached.  
 
Outpatient administration requires following for safety: i) alkalinization (e.g. method reported 
in this paper, sodium bicarbonate in daily IV fluids), ii) reliable patients (able to return for bag 
changes and laboratory exams), iii) facility and staff willing to see patients for laboratory 
exams, IV fluid questions and that troubleshoot clearance problems on a daily basis. 
 
Finally, the renal safety provided by this method allows the administration of HDMTX in the 
outpatient setting, which became a standard in our institution following the completion of this 
study. 
 
Beyond the renal safety provided by this method, we suggest that it might also allow the 
concomitant administration of HDMTX and other active drugs, for instance ifosfamide. 
Indeed, increasing the dose-intensity of neoadjuvant chemotherapy is a coherent approach in 
an effort to increase the proportion of patients with a high degree of necrosis in the primary 
tumour at the time of definitive surgery [7]. The degree of necrosis in the primary tumour 
predicts subsequent event-free survival (EFS) [23]. Previously published studies established 
the efficacy of neoadjuvant chemotherapy [24,25], but never demonstrated the superiority of 
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intensified neoadjuvant chemotherapy. For instance, a recent phase III study [26] compared 
two chemotherapy regimens associating doxorubicin and cisplatin, using two different dose-
intensities. The dose-intensive regimen was associated with an improved rate of good (> 90% 
necrosis) histologic responses: 36% vs. 50% (p = 0.003). Oddly enough, this improvement in 
histologic response rate did not result in improved progression-free survival or overall 
survival. To date, no randomized trial assessed the potential benefit of increasing the dose-
intensity of HDMTX and ifosfamide. We assume that our new schedule of administration of 
HDMTX could be a helpful tool for further studies aiming to evaluate the efficacy of a dose-





We demonstrated that hyper-alkalinization is an efficient and reliable method to prevent the 
acute renal toxicity of HDMTX in OS patients. Moreover, this method allows the safe 
administration of HDMTX in the outpatient setting. Further studies will determine whether 
this method allows the concomitant administration of HDMTX and other active drugs, which 
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Table 1: Solubility of MTX and its metabolites (mg/ml) [15] 
 
pH MTX 7-OH MTX DAMPA 
5.0 0.39 0.13 0.05 
6.0 1.55 0.37 0.10 
7.0 9.04 1.55 0.85 
 
Abbreviations: MTX, methotrexate; 7-OH MTX, 7-hydroxy methotrexate; DAMPA, 2,4-





Table 2: Leucovorin rescue according to methotrexate levels 48 hours after the start of 
HDMTX infusion [15] 
 
MTX concentration Leucovorin dose 
5 x 10
-7
 mol/l 15 mg/m² q6h x 8 
1 x 10
-6
 mol/l 100 mg/m² q6h x 8 
2 x 10
-6
 mol/l 200 mg/m² q6hx8 
 




Table 3: Patients characteristics (n = 26) 
 
Characteristic Results 
Median age (range) 18 (15-25) 






Primary site: n (%) 
 - Axial 




Median no. of cycles received (range) 11 (2-16) 
Baseline Scr (µmol/l), mean (  SD) 68.5 ( 21.5) 
EOT SCr (µmol/l), mean (  SD) 69.7 ( 17.5) 
Baseline CrCl (ml/min), median (range) 88 (72-159) 
EOT CrCl (ml/min), median (range) 92 (70-152) 
 
 
Abbreviations: EOT, end of treatment; SCr, serum creatinine; CrCl, creatinine clearance, SD: 
standard deviation. 
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HDMTX 8 g/m² 4 1088 ( 277.4) 12.57 ( 2.14) 0.48 ( 0.31) 4414 (3317-4955) 
HDMTX 12 g/m² 22 1266.9 ( 295.8) 25.48 ( 1.67) 1.82 ( 0.25) 5217 (3966-6118) 
  
 
